Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the granting of 111,250 restricted stock units (RSUs) to eight new employees as part of its 2022 Inducement Stock Incentive Plan on February 28, 2023. The RSUs will vest over three years with one-third vesting on each anniversary of employment. If a change in control event occurs, the RSUs can be exercised if employment is terminated for good reason or without cause. Karyopharm specializes in innovative cancer therapies, notably its lead XPO1 inhibitor, XPOVIO®, which is approved in various regions for multiple oncology indications.
- None.
- No immediate financial metrics or impacts on revenue are highlighted in the PR.
- Granting RSUs might signal potential future dilution of shares for existing investors.
NEWTON, Mass., March 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 111,250 restricted stock units (RSUs) to eight newly-hired employees. These RSU awards were granted as of February 28, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Each RSU award will vest over three years, with 33 1/
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301759003.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
What is the recent RSU grant by Karyopharm Therapeutics?
When were the RSUs granted by Karyopharm?
What is the vesting schedule for Karyopharm's RSUs?
What is Karyopharm Therapeutics' focus?